

Figure S1 OS of PCGF1 expression in BRCA, CESC, ESCA, KIRC, LUAD, LUSC, PAAD, PRAD, STAD, and UCEC (S1A-S1J). BRCA, breast invasive carcinoma; PCGF1, polycomb group factor 1; CESC, carcinoma and endocervical adenocarcinoma; ESCA, Esophageal carcinoma; KIRC, Kidney renal clear cell carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, Pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; UCEC, Uterine Corpus Endometrial Carcinoma; OS, overall survival.




Figure S2 Association of PCGF1 expression with clinical pathological characteristics in LIHC patients. (A) N stage; (B) M stage; (C) age; (D) Child-Pugh grade; (E) residual tumor; (F) gender; and (G) race. (ns, $P \geq 0.05$). PCGF1, polycomb group factor 1; TPM, transcripts per million; LIHC, liver hepatocellular carcinoma; ns, no significance.